Immunologic and virologic profiles of early, chronic, and LTNP HIV-1–infected patients and of healthy donors
| Cohort . | Time of infection, mo (y) . | Viral load,* copies RNA/mL . | CD4+ T cells/μL . | CD4+/CD8+ ratio . | Antiretroviral therapy . |
|---|---|---|---|---|---|
| Healthy donors (n = 70) | NA | NA | 1315 ± 216 | 1.21 ± 0.8 | NA |
| Early HIV-1 infection (n = 21) | 2 ± 1.9† (0.16 ± 0.16)† | 45 570 ± 99 453 | 815 ± 316 | 0.54 ± 0.25 | Naive |
| Chronic viremic HIV-1 infection (n = 96) | 67.9% ± 63.8‡ (5.7 ± 5.3)‡ | 59 381 ± 83 390 | 380 ± 207 | 0.4 ± 0.28 | Off therapy (≥ 24 mos) |
| Chronic LTNPs (n = 27) | 170.4 ± 63.6‡ (14.2 ± 5.3)‡ | < 50-660 (range) | 912 ± 321 | 1.2 ± 0.1 | Naive |
| Cohort . | Time of infection, mo (y) . | Viral load,* copies RNA/mL . | CD4+ T cells/μL . | CD4+/CD8+ ratio . | Antiretroviral therapy . |
|---|---|---|---|---|---|
| Healthy donors (n = 70) | NA | NA | 1315 ± 216 | 1.21 ± 0.8 | NA |
| Early HIV-1 infection (n = 21) | 2 ± 1.9† (0.16 ± 0.16)† | 45 570 ± 99 453 | 815 ± 316 | 0.54 ± 0.25 | Naive |
| Chronic viremic HIV-1 infection (n = 96) | 67.9% ± 63.8‡ (5.7 ± 5.3)‡ | 59 381 ± 83 390 | 380 ± 207 | 0.4 ± 0.28 | Off therapy (≥ 24 mos) |
| Chronic LTNPs (n = 27) | 170.4 ± 63.6‡ (14.2 ± 5.3)‡ | < 50-660 (range) | 912 ± 321 | 1.2 ± 0.1 | Naive |
Data are median ± SD.
NA indicates not applicable.
Plasma viremia was analyzed by an ultrasensitive bDNA assay (Chiron) with a lower limit detection of 50 copies per milliliter of plasma.
Range of time between the last seronegative screening for anti-HIV-1–specific mAbs and the first positivity to the test.
Since the time of first reported diagnosis.